Published in Women's Health Weekly, February 12th, 2004
Exagen is in the process of validating a breast cancer prognostic that will help physicians determine which newly diagnosed patients should consider aggressive treatment, and is developing a hepatitis C prognostic that will identify patients who are most likely to respond to treatment with interferon and ribaviran. The funding round was led by Tullis-Dickerson & Co. with the participation of vSpring Capital and Wasatch Venture Fund.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.